Sitemap
- About HMA
- Vision and mission
- Structure
- Working Groups
- Benchmarking of European Medicines Agencies (BEMA)
- EU Network Pharmacovigilance Oversight Group
- EU Network Training Centre (EU-NTC) - former OTSG
- EU-Innovation Network (EU-IN)
- HMA/EMA Joint Big Data Steering Group
- HMA Substances Validation Group
- HMA/EMA Joint Task Force on Availability of authorised medicines for human and veterinary use (TF AAM)
- HMA/EMA Joint Audit Programme (JAP)
- Telematics
- HMA Working Group of Biosimilars (BSWG)
- Working Group of Communication Professionals
- Working Group of Enforcement Officers
- HMA Working Group of Quality Managers
- European Medicines Agencies Co-operation of Legal and Legislative Issues (EMACOLEX)
- Clinical Trials Coordination Group
- Homeopathic Medicinal Products Working Group
- Periodic Safety Update Reporting (PSUR) - Synchronisation and Work-sharing
- Regulatory Optimisation Group (ROG)
- HMA Core Group for Medical Devices
- National Contacts
- COVID-19
- Combination products
- Transparency
- Meetings
- Medicines Approval system
- Publications and reports
- Recently Published
- Human Medicines
- CMDh
- About CMDh
- Statistics
- Agendas and Minutes
- Press Releases
- COVID-19
- BREXIT
- Nitrosamine impurities
- Procedural Guidance
- CMDh-Referrals
- Product Information
- Advice from CMDh
- Templates
- CMD Working Parties / Working Groups
- Paediatric Regulation
- Pharmacovigilance
- Falsified Medicines
- Questions & Answers
- Contact Points
- Recently Published history
- MRI Product Index
- Pharmacovigilance
- Availability of Medicines
- Publications and reports
- National Contacts
- CMDh
- Veterinary Medicines
- CMDv
- About CMDv
- Implementation of the VMP Regulation
- BREXIT
- Advice from CMDv
- Procedural Contact Points
- Procedural guidance
- Questions & Answers
- Publications
- Union Product Database (UPD)
- VMRI Product Index
- National Contacts
- CMDv